Format

Send to

Choose Destination
Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):e161-3. doi: 10.1016/j.clml.2014.06.004. Epub 2014 Jun 11.

Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.

Author information

1
Willamette Valley Cancer Institute, Eugene, OR. Electronic address: Jeff.Sharman@USOncology.com.
2
Foundation Medicine Inc, Cambridge, MA.
3
Foundation Medicine Inc, Cambridge, MA; Albany Medical College, Albany, NY.
4
Willamette Valley Cancer Institute, Eugene, OR.

KEYWORDS:

Mitogen-activated protein kinase; Mutation; Refractory myeloma; V600E; Vemurafenib

PMID:
24997557
DOI:
10.1016/j.clml.2014.06.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center